Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of upper and lower motor neurons that results in progressive motor impairment. ALS is the most common disease of motor neurons with an annual incidence of approximately 1.7–2.5 per 100,000 people. It is a ...

Brain Awareness Week, taking place from March 10-16, 2025, is a global campaign dedicated to fostering public enthusiasm and support for brain science, organised by the Dana Foundation. Each March, participants worldwide organize imaginative activities that highlight the wonders of the brain and the profound impact of neuroscience on our daily lives.

Huntington’s disease (HD) is a neurodegenerative disease inherited in an autosomal dominant manner. It is caused by an expansion of cytosine, adenine, guanine (CAG) repeats within the huntingtin (HTT) gene, which is located on chromosome 4. This pathological expansion of ...

Explore ground-breaking advancements in the treatment of movement disorders in this insightful interview with Prof. K. Ray Chaudhuri, who shares his key takeaways from the 10th Congress of the European Academy of Neurology meeting in Helsinki. He discusses promising new therapies, personalized care approaches, and significant research on the staging of Parkinson's. Additionally, Prof. Chaudhuri emphasizes the importance of holistic treatment, stepped-care strategies, remote management, and the potential of wearable technology in improving patient outcomes, bringing his wealth of knowledge and insights to touchNEUROLOGY

Key highlights from the 10th Congress of the European Academy of Neurology (EAN) in Helsinki (EAN2024).

In the latest edition of touchREVIEWS in Neurology, we are pleased to present a collection of insightful articles that highlight the current landscape and future directions in neurological research and treatment. Firstly, Rajvinder Karda opens this issue with a compelling ...

Huntington’s disease (HD) is a genetic neurodegenerative disease that can affect movement, cognition and mental health. It is caused by a dominant mutation in the huntingtin gene, HTT. HD is estimated to occur in 5–10 people per 100,000 yearly, worldwide.1 Pridopidine (...

The phase 2 study results of ANX005, a humanized monoclonal antibody targeting C1q, for patients with Huntington’s disease were presented at MDS 2022. In this touchNEUROLOGY interview, we speak with Dr Rajeev Kumar (Rocky Mountain Movement Disorders Center, Englewood, CO, ...

ANX005, a humanized monoclonal antibody, is designed to inhibit the classical complement pathway which has been associated with Huntington’s disease (HD). In this touchNEUROLOGY interview, we speak with Dr Rajeev Kumar (Rocky Mountain Movement Disorders Center, Englewood, CO, USA) ...